Petros Pharmaceuticals (NASDAQ:PTPI) Trading Up 30.4% – Time to Buy?

Petros Pharmaceuticals, Inc. (NASDAQ:PTPI)’s share price shot up 30.4% on Monday . The company traded as high as $0.44 and last traded at $0.42. 1,777,419 shares changed hands during trading, an increase of 222% from the average session volume of 551,506 shares. The stock had previously closed at $0.32.

Petros Pharmaceuticals Stock Performance

The stock has a market capitalization of $2.92 million, a P/E ratio of -0.06 and a beta of 2.12. The company has a current ratio of 1.40, a quick ratio of 1.26 and a debt-to-equity ratio of 0.71. The company has a 50-day moving average price of $0.34 and a two-hundred day moving average price of $0.48.

Petros Pharmaceuticals (NASDAQ:PTPI) last issued its earnings results on Wednesday, August 14th. The company reported ($0.37) earnings per share for the quarter. The business had revenue of $1.42 million during the quarter.

About Petros Pharmaceuticals

Petros Pharmaceuticals, Inc, a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED).